OSLO, Norway, Feb.
14, 2019 /PRNewswire/ -- Targovax ASA (OSE:
TRVX), a clinical stage biotechnology company developing immune
activators to target hard-to-treat solid tumors, today announces
its fourth quarter and full year 2018 results.
A meeting for investors, analysts and press will take place
in Oslo today at 10:00 CET (details below).
HIGHLIGHTS FOR THE FOURTH QUARTER 2018
- In October, the Company reported the full data set from the
TG01 trial in resected pancreatic cancer. The trial showed six
months improvement in median overall survival (mOS) data over
comparable historical control trials and RAS-specific immune
activation in 94% of patients
- In October, the Company hosted a Key Opinion Leader Symposium
on oncolytic viruses in New York
City, with speakers from Memorial Sloan Kettering Cancer
Centre presenting an overview of the oncolytic virus space and
encouraging interim data from the ONCOS-102 trial in CPI refractory
advanced melanoma
POST-PERIOD HIGHLIGHTS
- In January 2019, Targovax
announced that the European Patent Office has granted a European
Patent which protects Targovax' mutant-RAS specific neoantigen
peptides, mutant RAS specific T-cells and vaccines TG01 and TG02,
for the treatment of cancer in combination with chemotherapies.
This extends the IP protection of TG01 and TG02 into 2034
- In February 2019, Targovax
announced that the first patient has been treated in the dose
expansion cohort of the ONCOS-102 trial in melanoma
Øystein Soug, CEO commented: "2018 was the year when
we really started to see data read-outs from our two immune
activator programs. ONCOS showed the first signs of efficacy in
combination trials with both check-point inhibitors and
chemotherapy. TG became the first therapeutic cancer vaccine to
clinically demonstrate T-cell activation towards a driver mutation,
mutant RAS, combined with a clear signal of survival benefit in
resected pancreatic cancer patients. We now look forward towards
2019 and 2020 as we continue to progress our clinical program and
unlock the full potential of both of these platforms
Presentation
The presentation will take place at 10:00
CET at:
Hotel Continental
Stortingsgaten 24/26
0117 Oslo
The presentation will also be webcast live and can be accessed
here.
Reporting material
TRVX 4Q18 report
TRVX 4Q18 presentation
The quarterly report and presentation are also available at the
website www.targovax.com.
For further information, please contact:
Renate Birkeli,
Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/targovax/r/targovax-asa--fourth-quarter-and-full-year-2018-results,c2740751
The following files are available for download:
https://mb.cision.com/Public/17093/2740751/aa3eb29d7fd79595.pdf
|
TRVX 4Q18
presentation
|
https://mb.cision.com/Public/17093/2740751/a56636b387f3359f.pdf
|
TRVX 4Q18
report
|
View original
content:http://www.prnewswire.com/news-releases/targovax-asa-fourth-quarter-and-full-year-2018-results-300795624.html
SOURCE Targovax